Enveda, a biotech startup that uses AI to discover new drugs in the natural world, has raised a $311 million Series E at a $2 billion valuation. The fresh funding, which was led by Catalio Capital Management, with participation from Iconiq and others, doubles the valuation Enveda achieved 12 months ago. The idea behind Enveda
Digital wearables are currently used to monitor glucose, but could potentially be used to measure substances such as glutamate and cortisol.Credit: Halfpoint Images/Getty The year is 2036. Researchers conducting a randomized clinical trial issue 200 volunteers with wearable devices to capture metrics on their heart rate, blood pressure, hormone levels and activity. Doses of a
Under China’s Order 818, only high-level hospitals will be able to conduct investigator-initiated trials (IITs).Credit: Xinhua/Shutterstock In the past two months, reports that two children died after receiving gene-editing treatments in separate clinical trials in China have put a spotlight on the country’s fast-track trial pathway. Investigator-initiated trials (IITs) are a popular way that researchers
Kalshi and Polymarket say allowing people to bet on the outcomes of clinical trials and FDA drug approvals provides valuable information about drug development. But researchers warn the bets could incentivize insider trading and interfere with the integrity of the process. Fred Tanneau/AFP via Getty Images hide caption toggle caption Fred Tanneau/AFP via Getty Images
